Ou SY, Lee YJ, Lo Y, et al. - Renin‐angiotensin‐aldosterone system inhibitors (RAASis) are usually discontinued during hospitalization for sepsis because of concerns about renal hypoperfusion.  Researchers investigated whether sepsis survivors should be continued on RAASis after discharge and examined the effects of continuation on the clinical outcomes.

• For inclusion in the analyses, researchers identified a total of 9,188 sepsis survivors aged 20 years and older, who were discharged from January 1, 2012 to December 31, 2019.

• After propensity score matching, the analyses were performed including 3,106 RAASi users and 3,106 RAASi nonusers.

• RAASi users were noted to have decreased risks of all‐cause mortality and major adverse cardiac events (MACE).

• RAASi use after discharge appears as beneficial for sepsis survivors.